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treatment. We are pleased to learn that this hypothesis was
conﬁrmed by Halfon et al. in their clinical practice.
In summary, the combination therapy of PegIFN alfa-2a
and NA can be beneﬁcial, but the optimal strategies for com-
bination remains to be determined. With newly developed
therapeutic regimens appearing in the near future, including
cytokines, HBV entry blockers, Toll-like receptor agonists,
and therapeutic vaccines, it is conceivable that use of these
additional immunomodulators rather than IFN, might be of
synergic beneﬁt in the restoration of innate and adaptive
immune responses in CHB patients (Fig. 1). Currently two ran-
domized, multicentre, comparative and prospective clinical
trials (Endeavor and Anchor study), involving combination
therapies of IFN, NA and immunomodulators (cocktail therapy)
for NA-treated CHB patients, are under way in China to
explore this hypothesis.
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JOURNAL OF HEPATOLOGYALPPS procedure for hepatocellular carcinoma with macrovascular
thrombosis: A new opportunity?To the Editor:
We read with interest the recent article entitled, ‘‘Surgical treat-
ment of hepatocellular carcinoma associated with hepatic vein
tumour thrombosis’’ published by Kokudo et al. [1]. We congratu-
late the authors for their study, based on an experience of over
1500 liver resections. The authors conclude that surgical treat-
ment of patients with tumour thrombosis, involving major hepa-
tic veins (mHVTT), does not differ in terms of mortality, length of
hospital stay and frequency of complications compared with
patients with microscopic invasion (pHVTT). We agree with the
authors’ conclusion. Major hepatectomy was performed in 67%
of the cases in the mHVTT group, including four where right
extended or left hepatectomy was required. We would like to
draw attention to those selected patients. Since the ﬁrst two-
staged hepatectomy reports [2], liver resection indications have
been implemented with new surgical treatments, such as the
Associating Liver Partition and Portal vein ligation for Staged hep-
atectomy (ALPPS) procedure. Vennarecci et al. [3] described the
ALPPS procedure for hepatocellular carcinoma (HCC) with major
vascular invasion and concluded that this technique may increaseJournal of Hepatology 2015 vol. 62 j 238–251 241
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Letters to the Editor
the rate of curative liver resections for tumours previously consid-
ered unresectable. Kokudo et al. [1] considered surgical resection
of cases where preoperative characteristics jeopardize oncological
radicality, only with the intent to prevent embolic complications
or tumour rupture. The authors suggested that this aggressive sur-
gical approach should be considered only in Child-Pugh class A
patients, in which liver function is still acceptable. We agree with
this statement. A multicentre analysis recently conﬁrmed that the
ALPSS procedure offers a better chance for complete resection in
patients with primarily unresectable liver tumours [4]. In another
study, ALPPS has been described for cirrhotic patients with HCC
[5], in which all resected cases had preserved liver function
(Child-Pugh class A). An increase in the future liver remnant
(FLR) from 33% to 43% was observed within one week; this
increase reached 54% after hepatectomy. These important results
suggest that it is possible to achieve R0 resection in patients with
mHVTT as long as patients present preserved liver function. Not-
withstanding, ALPPS represents a suitable indication only in a
small number of patients with portal vein thrombosis (PVT). In
fact, patients treatable with ALPPS should be carefully selected
and evaluated in order to draw a beneﬁt in terms of survival.
Model for end-stage liver disease (MELD) and portal hypertension
(PHT) are two crucial factors in decision making for surgical
resection, especially when major liver resection or the ALPPS pro-
cedure are contemplated. As previously described, liver resection
in cirrhotic patients withMELD score >14 is not recommended [6],
and when the score is >9 other treatment modalities should be
considered [7]. PHT was for a long time considered an absolute
contraindication for liver resection. However, recent experiences
suggest that liver surgery can be safety achieved also in the pres-
ence of PHT, mainly in the case of limited hepatic resections in
patients with Child-Pugh A [8–10]. Nevertheless, we believe that
PHT must remain a contraindication for ALPPS procedure as well
as for major hepatic resections. According to the classiﬁcation of
PVT by Shi et al. [10] we suggest type III-IV as contraindications
for the ALPPS procedure, whilst type I-II can be safely approached
with this surgical technique. The suboptimal effect on the
regeneration of truncal with respect to segmental/subsegmental
PVT must also be taken into account. Various grades of liver atro-
phy consequent to truncal/main PVT can be preoperatively evalu-
ated with volumetric computed tomography (volCT), calculating
in this way the liver remnant to body weight ratio (BWR). The vol-
CT scan can be repeated after the ﬁrst surgical step, starting from
postoperative day 7. Patients can be scheduled for the second step
when a liver remnant to BWR of 0.8 was achieved. Consistent with
these arguments, ALPPS seems to be an intriguing strategy, which
should be explored in the next future. ALLPS can represent a valid
approach also in patients with mHVTT, with the intent to increase
the surgical indications.
In conclusion, we hope that further studies will focus their
attention on patients with HCC that are presently considered
unresectable. Multicentre studies are aimed to better deﬁne
indications for HCC in cirrhotic patients with hepatic vein tumour
thrombosis.242 Journal of Hepatology 2015 vol. 62 j 238–251
